Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Natalizumab Treatment of Progressive Multiple Sclerosis

NCT01077466 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT01077466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01077466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Natalizumab Treatment of Progressive Multiple Sclerosis
Lead sponsor
Rigshospitalet, Denmark
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
January 31, 2012
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis, secondary progressive multiple sclerosis